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Abstract 
Drug delivery systems (DDS) have become important tools for the specific 
delivery of a large number of drug molecules. Since their discovery in the 1960s 
liposomes were recognized as models to study biological membranes and as 
versatile DDS of both hydrophilic and lipophilic molecules. Liposomes, - 
nanosized unilamellar phospholipid bilayer vesicles - undoubtedly represent the 
most extensively studied and advanced drug delivery vehicles. After a long 
period of research and development efforts, liposome-formulated drugs have 
now entered the clinics to treat cancer and systemic or local fungal infections, 
mainly because they are biologically inert and biocompatible and practically do 
not cause unwanted toxic or antigenic reactions. A novel, up-coming and 
promising therapy approach for the treatment of solid tumors is the depletion of 
macrophages, particularly tumor associated macrophages with bisphosphonate-
containing liposomes. In the advent of the use of genetic material as therapeutic 
molecules the development of delivery systems to target such novel drug 
molecules to cells or to target organs becomes increasingly important. 
Liposomes, in particular lipid-DNA complexes termed lipoplexes, compete 
successfully with viral gene transfection systems in this field of application. 
Future DDS will mostly be based on protein, peptide and DNA therapeutics and 
their next generation analogs and derivatives. Due to their versatility and vast 
body of known properties liposome-based formulations will continue to occupy a 
leading role among the large selection of emerging DDS.  
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1. Introduction 
 
1.1 State of the art of nanosized drug delivery systems. The first 
microencapsulated drugs were introduced in the 1950s and polymer based slow 
release systems appeared shortly thereafter. Soon after their discovery in the 
1960s by A.D. Bangham and colleagues, liposomes – phospholipid bilayer 
nanocontainers with spherical shape properties - were recognized as potential 
drug delivery systems (DDS).1,2 Since then a tremendous amount of work on 
applications of liposomes has been accomplished. Due to their versatility 
nanosized small unilamellar liposomes are used as models to study biological 
and biophysical membrane properties and as carriers of drugs for therapeutic 
applications. Liposomes undoubtedly represent today the most extensively and 
advanced drug delivery vehicles. Liposome-formulated drugs have entered the 
clinics to treat cancer and systemic or local fungal infections, mainly because 
they are biologically inert, biocompatible and practically do not cause unwanted 
toxic or antigenic reactions and, most importantly, industrial large-scale 
production of liposome formulated drugs has allowed their advance in the 
pharmaceutical industry.3-5
 In the advent of the use of genetic material (DNA, ribozymes, DNAzymes, 
aptamers, (antisense-) oligonucleotides, small interfering RNAs) as therapeutic 
molecules the development of delivery systems to target these molecules to cells 
or to target organs becomes increasingly important. In this field the liposomes, in 
particular lipid-DNA complexes termed lipoplexes (see below), compete with viral 
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gene transfection systems. Nanoparticles, nanospheres, polymersomes, 
nanogels, micelles, dendrimers, and virosomes are other main types of 
nanocarrier systems used for drug delivery.6-11 As schematically shown in Fig. 1, 
modern DDS including polymer-drug conjugates, liposomes, osmotic pumps, 
microchips, wafers, transdermal patches and other systems vary in their 
concepts, compositions, shapes, sizes, drug loading capacity as well as in their 
pharmacokinetic and organ distribution properties.12 All DDS, however, pursue 
the aim of improving drug delivery for the benefit of the patient. 
 The major applications of DDS comprise drugs that possess non-ideal 
physico-chemical and pharmacological properties such as 1) Poor solubility; 2) 
Tissue damage caused by unintentional extravasation of drugs; 3) Loss of drug 
activity following administration; 4) Unfavorable pharmacokinetic properties and 
poor biodistribution and 5) Lack of selectivity for target organs or tissues. 
Systemic drug distribution may cause toxic side effects and low drug 
concentrations at target tissues; this could lead to suboptimal therapeutic effects.  
 The formulation of pharmacologically active drug molecules in DDS can 
improve or abolish these unfavorable properties. However, there are also 
disadvantages in the development of particulate drug carriers, such as system 
complexity, unwanted biologic and immunologic effects, stability, costs of 
development and scale-up, as well as intellectual property issues. In the limited 
format of this chapter it is not possible to cover all methods and references from 
the vast field of liposome technology. Hence, we concentrate on summarizing 
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use and properties of liposomes as DDS for the delivery of cytotoxic molecules 
for cancer therapy.  
 
1.2 Evolution of Liposomes in cancer therapy.  Liposomes have become 
known as one of the most versatile tools for the delivery of pharmacologically 
active molecules. Since their discovery in the 1970s their potential for the 
delivery of cytotoxic drugs in cancer therapy has been recognized.4,5,11,13,14 
 Liposomes are spherical vesicles that consist of an aqueous compartment 
enclosed by a phospholipid bilayer. If multiple bilayers of lipids are formed 
around a primary core, the structures that are generated are termed multilamellar 
vesicles (MLVs). MLVs are formed spontaneously upon reconstitution of dry lipid 
films in aqueous media. Small (nanosized) unilamellar vesicles (SUVs) of 
scaleable mean diameters of 20 to 500 nanometers are produced by high 
pressure extrusion of MLVs through polycarbonate membranes. SUVs are also 
obtained by ultrasonication, by detergent dialysis and by many other, less 
important methods. Hydrophilic and hydrophobic drugs can both be entrapped in 
liposomes. Since the composition of the liposome bilayers can be varied with a 
huge selection of different phospholipids and additional intercalating molecules, 
liposomal delivery systems are of high versatility and customized formulations 
can easily be engineered to obtain desired sizes, surface charge, membrane 
composition and morphology providing them with high versatility such as long 
circulation half-life, sustained and targeted drug delivery or diagnostic imaging 
properties.11,15-19 
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 As schematically shown in Fig. 2, the liposomes evolved from rather 
simple compositions (Fig. 2A, B) to highly sophisticated multi-component 
systems. The state-of-the-art liposomes used for parenteral drug delivery are the 
long circulating (“stealth”) liposomes (Fig. 2C, D, E). Stealth liposomes are 
sterically stabilized formulations that include polyethylene glycol (PEG)-
conjugated lipids or other hydrophilic coating molecules. The surface grafted 
polymers create an impermeable, highly hydrophilic layer on the outer liposome 
surface. The prominent properties of long-circulating liposomes are dose-
independent, non-saturable, log-linear pharmacokinetics and increased 
bioavailability. Pegylation prevents or retards opsonization and recognition of the 
liposomal vesicles by the monocytic phagocyte system (MPS).11 Due to their long 
circulation time in blood and the enhanced drug permeability and retention effect 
in tumor tissues, PEG-liposomes accumulate at high concentrations (up to 10% 
of the injected dose per organ) in tumors.20-24 
 Immunoliposomes (Fig. 2B, D) are complex drug or gene delivery systems 
that are developed for specific cell targeting by attachment of functionalized 
antibodies or antibody fragments to the outer surface of the liposomes. The 
modern immunoliposomes are PEG-liposomes to which receptor specific 
molecules are attached, preferably at the distal tips of the PEG chains (Fig. 2E, 
j). Immunoliposomes target cell specific receptors and facilitate receptor-
mediated endocytosis for cell uptake.25
 A variety of tumor-specific antibodies have been used for targeting of 
liposomes to tumor cells or molecules located in the tumor stroma. In earlier 
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studies whole IgG antibodies were linked to the liposome surface by various 
coupling methods.26 Today the most advanced immunoliposomes are the anti-
p185/HER2 liposomes that target the herceptin receptor which is over-expressed 
in various cancers, especially breast cancer. Long-circulating immunoliposomes 
targeted to HER2 (ErbB2, Neu) have been prepared by conjugation of anti-HER2 
MAb fragments (Fab' or single chain Fv, scFv) to liposome-grafted polyethylene 
glycol chains. MAb fragment conjugation did not affect the biodistribution or long-
circulating properties of i.v.-administered liposomes.27-29 The epidermal growth 
factor receptor (EGFR) is another target for immunoliposomes that bind to and 
internalize in tumor cells that over-express EGFR. Anti-EGFR immunoliposomes 
have been constructed modularly with Fab' fragments of the antibody 
cetuximab.30-32 A large number of antibodies directed against other target 
molecules expressed on colon33, B-cell lymphoma34, and neuroblastoma35 
tumors have been used for the preparation of immunoliposomes. In order to 
target the ED-B isoform of fibronectin, which is exclusively expressed in the 
extracellular matrix of solid tumors, we constructed immunoliposomes decorated 
with scFv antibody fragments directed against ED-B fibronectin and successfully 
used these DDS for targeted delivery of cytotoxic drugs into tumors in vivo.36 We 
also developed specific antibodies and immunoliposomes for specific targeting of 
tumor endothelial marker (TEM1) and the vascular endothelial growth factor 
receptor-2 (VEGFR-2).37,38 Tissue-specific gene delivery using immunoliposomes 
has also been achieved with folate39,40 and transferrin41 receptor specific 
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immunoliposomes. Additionally, tumor vasculature targeted immunoliposome 
therapy was shown to be effective with liposomal doxorubicin.42-44
 Various cell uptake mechanisms for liposomes have been described.8,45 
Due to their particulate properties, phagocytic uptake mechanisms (phagocytose, 
endocytose, pinocytose) are predominant, however cell membrane adhesion and 
fusion can also occur. In the phagocytic uptake pathway liposomes are captured 
at the cell surface followed by endosomal and lysosomal uptake. Drug liberation 
into the cytoplasm depends on the lipid composition of the liposomes. To release 
encapsulated material into the cytoplasm of a cell, pH-sensitive liposomes can be 
generated by addition of dioleylphosphatidyl-ethanolamine (DOPE) to liposomes 
composed of acidic lipids such as cholesterylhemisuccinate (CHEMS) or oleic 
acid and other lipids. At a pH of 7, these lipids possess the typical bilayer 
structure; however, upon endosomal compartmentalization (pH becomes more 
acidic) they undergo protonation and collapse into non-bilayer structures. This 
leads to the disruption and destabilization of the endosomal membrane, which in 
turn promotes rapid release of encapsulated molecules into the cytoplasm.8  
 Cell penetrating peptides (CPPs) have proven to be efficient intracellular 
delivery systems overcoming the lipophilic barrier of cell membranes. CPPs can 
deliver a wide range of large cargo molecules such as proteins, peptides, 
oligonucleotides and even small nanoparticles as liposomes to a variety of cell 
types and to different cellular compartments. The CPPs are basic, lysine- or 
arginine- rich amphipathic peptides originating from different sources. CPPs can 
either form complexes with many different types of molecules (peptides, proteins, 
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plasmids, oligonucleotides, siRNA, dyes etc.) or they can be covalently linked to 
these cargo molecules.46,47 Liposomes have also been decorated with the TAT48 
or pAntp CPPs49, demonstrating higher cell uptake rates in vitro. Regrettably, 
their usefulness as drug delivery systems is hampered by their ability to 
penetrate virtually any cell type both in vitro and in vivo in a non-specific mode. 
This feature complicates CPP applications as target specific drug delivery 
systems; therefore therapeutic applications seem unlikely, unless their target cell 
specificity can be significantly improved.  
 
1.2.1 Liposomes as carriers of lipophilic and amphiphilic nucleoside analogs. The 
majority of applications of liposomes as therapeutic DDS are based on the 
encapsulation of water soluble cytotoxic molecules within the trapped aqueous 
volume of the liposomes. Liposomes loaded with cytotoxic anti-tumor drugs 
doxorubicine, mitoxantrone, topotecan, irinotecan and cytarabine are examples 
of clinically applied chemotherapeutic liposome formulations. 5,11,15,16,22,50-55 For a 
current summary of clinically used liposomal anti-cancer formulations see 
reference 22. In contrast to the extensive exploitation of the trapped aqueous 
volume of the liposomes that serves as nanocontainer for water soluble 
molecules, the phospholipid bilayer has not been given the same attention for its 
use as carrier matrix for lipophilic drugs. Hence, the development of liposomal 
drug formulations with lipophilic drugs is less popular. This difference may have 
several reasons with the main reason being that the chemistry required to 
transform water soluble molecules into lipophilic compounds allowing 
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incorporation into the lipid bilayer core is difficult. The most favorable chemical 
modifications consist in the attachment of long chain fatty acyl or alkyl residues, 
for example saturated or unsaturated fatty acids, preferably palmitic or stearic 
acid and alkylamines, preferably hexadecyl- or octadecylamine to a suitable 
functional group of the hydrophilic part of the drug molecule. Some recent 
examples of lipophilic modifications of antitumor drugs and their formulation in 
liposomes are gemcitabine, 5-iodo-2’-deoxyuridine, methotrexate, paclitaxel and 
a lipophilic topoisomerase inhibitor.56-62
 Drugs that are highly lipophilic by their own nature, e.g. taxanes and 
epothilones can only be used therapeutically by addition of possibly toxic 
solubilizing agents (e.g. Cremophor EL) in complex pharmaceutical 
formulations.63,64 One of several feasible means of obtaining non-toxic 
parenterally applicable formulations of such drugs is their incorporation into the 
bilayer matrix of phospholipid liposomes.65 
 Nucleoside analogs are a major class of chemotherapeutic agents for the 
treatment of cancer and viral diseases. Natural endogenous nucleosides must be 
phosphorylated to corresponding 5`-triphosphates in order to be incorporated into 
the DNA or RNA synthesised within the cell. Nucleoside analogs are in essence 
prodrugs since they must undergo the same transformations in the cytoplasm 
similarly to the natural nucleosides before becoming active. We chose the 
approach of chemical transformation of water-soluble nucleosides of known 
cytotoxic and antiviral properties into lipophilic drugs or prodrugs, thus reversing 
the paradigm of transforming lipophilic molecules into hydrophilic derivatives. The 
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first cytotoxic nucleoside we chose is 1-β-D-arabinofuranosyl cytosine (ara-C) 
because its major clinical disadvantages are a very short plasma half-life and 
rapid inactivation. To reduce these limitations, a large number of 5'- and N
4
-
substituted ara-C derivatives have been synthesized and characterized in the 
past (reviewed in reference 66). Of a series of N
4
-alkyl-ara-C derivatives with 
alkyl chain lengths ranging between 6 and 22 C-atoms, N4-octadecyl-ara-C 
(NOAC) exerted the strongest anti-tumor activity after oral and parenteral therapy 
in several mouse tumor models and showed to have distinct pharmacological 
properties compared to ara-C.  67,68 Of note, reference 69 provides an excellent 
review of the topic. 
  Consequently, we further modified NOAC by the synthesis of a new 
generation of lipophilic/amphiphilic heterodinucleoside phosphate derivatives, 
termed “duplex drugs” that combine the clinically used antitumor drugs ara-C and 
5-fluorodeoxyuridine (5-FdU) with NOAC to the heterodinucleoside phosphates 
arabinocytidylyl-N4-octadecyl-1-β-D-arabinofuranosyl cytosine (ara-C-NOAC) and 
2’-deoxy-5-fluorouridylyl-N4-octadecyl-1-β-D-arabinofuranosyl cytosine (5-FdU-
NOAC).70,71 Ethynylcytidine (1-(3-C-ethynyl-β-D-ribo-pentafuranosyl)-cytosine, 
ETC) is a novel nucleoside that was found to be highly cytotoxic.72 Its 
combination with NOAC yields the lipophilic duplex drug ETC-NOAC (3’-C-
ethynylcytidylyl-(5’→5’)-N4-octadecyl-1-β-D-arabinofuranosyl cytosine). Due to 
the combination of the effects of both active molecules that can be released into 
the cytoplasm as monomers or as the corresponding monophosphates (MP), the 
cytotoxic activity of the duplex drugs is expected to be more pronounced as 
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compared to the monomeric drugs. Further, it can be anticipated that the 
monophosphorylated nucleosides ara-CMP, 5-FdU-MP and ETC-MP, 
respectively, are directly released in the cell after enzymatic cleavage of the 
parent drugs. Thus, monophosphorylated molecules do not need to pass the first 
phosphorylation step, which is known to be rate limiting.73,74 The lipophilic side 
chains warrant a stable incorporation of these duplex drugs into liposomes, 
allowing the exploitation of the liposome formulations advantages.  
 We conclude that the chemical modification of water-soluble molecules by 
attachment of long lipophilic chains and their stable incorporation into bilayer 
membranes of small unilamellar liposomes represent very promising examples of 
taking advantage of the high loading capacity lipid bilayers offer for lipophilic 
drugs. The combination of chemical modifications of water soluble drugs with 
their pharmaceutical formulation in liposomes is a valuable method for the 
development of novel pharmaceutical preparations not only for the treatment of 
tumors or infectious diseases, but also for many other disorders. 
 
1.2.2 Liposome-mediated depletion of tumor associated macrophages. The 
physical depletion of macrophages located in organs of the monocytic phagocyte 
system (MPS; spleen, liver, lymph nodes, bone marrow) by liposome 
encapsulated clodronate (clodrolip) has become an important and reliable 
method to study the roles of macrophages in the immune system and in 
inflammatory processes.75-78 Even though the infiltration of macrophages into 
solid tumors and their pro-tumorigenic function has been described three 
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decades ago, their use as potential therapeutical targets is only now being 
discussed.79-82 Tumor cells shed chemokines that attract macrophages from the 
peripheral circulation. These macrophages infiltrate the stroma of solid tumors 
and accumulate in hypoxic tumor tissue. Tumor associated macrophages (TAMs) 
play a pivotal role in tumor growth and metastasis by promoting tumor 
angiogenesis. Recently, we have investigated whether the depletion of TAMs 
would inhibit tumor angiogenesis and consequently tumor growth. We show that 
TAM depletion mediated by clodrolip inhibits tumor growth, presumably through 
blocking tumor angiogenesis and promoting tumor cell starving. Clodrolip are 
liposomes containing the drug dichloromethylenebisphosphonic acid (also known 
as clodronate).  In our experiments, tumor bearing mice were treated with 
clodrolip as single therapy in comparison to free clodronate and in combination 
with anti-VEGF single chain fragment antibodies, resulting in drastic tumor 
growth inhibition and exhaustion of TAM cell populations.83 In a representative 
experiment shown in Fig. 3 we treated mice bearing syngeneic F9 
teratocarcinoma tumors with clo dronate and the lipophilic heterodinucleotide 
duplex drug 5-FdU-NOAC, both applied in liposome formulations. Macrophage 
depletion combined with a cytotoxic therapy was highly effective in this tumor 
model. Based on our results we conclude that clodrolip mediated depletion of 
TAMs in concert with cytotoxic or anti-angiogenic treatment regimens represents 
a new and highly effective therapeutic modality for the treatment of solid tumors 
and prevention of metastasis. Further, this is an interesting tool for the study of 
macrophage function in solid tumors. 
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1.2.3 Cationic liposomes and lipoplexes as DNA delivery systems. Liposomes 
can be used as DNA drug delivery systems either by entrapping DNA-based 
therapeutics inside the aqueous liposome core or by complexing them to 
positively charged lipids (lipoplexes, see below). Liposomes offer significant 
advantages over viral delivery systems. They are generally non-immunogenic 
because of the absence of protein components. Liposome encapsulated DNA 
molecules are protected from nuclease activity for enhanced biological stability. 
Cationic polymers have an enormous potential for DNA complexation and have 
shown to be useful as non-viral vectors for gene therapy applications. In past 
years, liposomes composed of cationic lipids, termed lipoplexes, have routinely 
been utilized for the delivery of nucleic acids such as plasmids, 
oligodeoxynucleotides and siRNA to cells in culture and in vivo. A large number 
of these reagents are commercially available or can be formulated in the 
laboratory.7-9, 84-91 The majority of cationic lipid-DNA complexes form a 
multilayered structure with DNA molecules intercalated between the cationic 
lipids. An inverted hexagonal structure with single DNA strands encapsulated in 
lipid tubules is observed rarely.92 Together with other advantages the lipoplexes 
have the ability to transfer very large genes into cells. However, the 
understanding of their mechanisms of action is still incomplete and their cell 
transfection efficiencies remain low compared to those of viruses. Despite the 
appreciable success of cationic lipids in gene transfer, toxicity is a main issue for 
both in vitro and in vivo applications. Inflammatory toxicity represents a typical 
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effect associated with systemic administration of lipoplexes. Recent results 
indicate that lipoplex gene delivery systems mediate uptake of plasmid DNA by 
the liver, mainly by the phagocytic Kupffer cells, in which a large amount of 
cytokines is produced.93 In addition, these complexes are immunostimulatory, a 
property that may either be harmful or beneficial. Another disadvantageous 
property of lipoplex mediated gene transfer are the low transfection efficiencies; 
which have been attributed to the heterogeneity and instability of the lipoplex 
formulations. Lipoplex size heterogeneity also adversely affects their quality 
control, scale-up, and long-term shelf stability, which are important issues for 
pharmaceutical development. Another unwanted property of cationic lipids is the 
rapid inactivation of their cargo in the presence of serum proteins.94 Development 
of optimized cationic lipids that are safe to use for in vivo applications is an 
ongoing process. A cautionary note to the potential dangers of all viral gene 
products, transgenes, viral proteins and peptides and CpG DNA sequences in 
siRNA or plasmids formulated in liposomes or other DDS has to be given. 
Immune responses induced by these molecules may lead to problems such as 
transient gene expression, non-efficient re-administration of the same vectors 
and to severe side-effects in clinical trials.95 Due to their particulate nature, the 
DDS are recognized as foreign and thus elicit immune reactions of the host 
organism. However, the immunomodulating activities of the DDS depend largely 
on their composition, size and homogeneity. Synthetic polymers can exhibit 
significant immunomodulatory activity, whereas liposomes prepared with natural 
phospholipids and cholesterol are known to be less immunogenic. 
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2. Outlook and future directions. 
The development of DDS is an ongoing challenging venture that combines 
multidisciplinary research efforts in various areas including bioengineering, 
nanotechnology, biomaterials, pharmaceutics, biochemistry, and cell and 
molecular biology. Specific characteristics of pathological processes and cell or 
tissue types that are subject of therapeutic interventions govern the path from 
target selection to the development of specific DDS formulations. The 
identification of novel cellular targets, for example easily accessible vascular 
endothelial cells, in contrast to tumor cells or other less targetable tissues, will 
lead to optimized pharmaceutical drug delivery formulations and preparation 
technologies. Refinement of DDS in order to overcome unwanted properties such 
as toxicity, non-specific tissue distribution and uncontrolled release of entrapped 
active molecules will be the major challenges in the field. Future DDS will mostly 
be based on protein, peptide and DNA therapeutics and their next generation 
analogs and derivatives. Liposome-based formulations will continue to occupy a 
leading role among the large selection of emerging DDS due to their versatility 
and vast body of known properties.  
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Figure legends 
 
Figure 1. Modern drug delivery systems. There are a variety of different 
delivery strategies that are either currently being used or are in the testing stage 
to treat human cancers and other diseases. Examples of these include polymer 
microspheres, polymer wafers, osmotic pumps, liposomal systems, polymer/drug 
targeting moiety conjugates, and controlled release microchips.  Reprinted with 
permission from Elsevier (ref. 12). 
 
Figure 2. Evolution of liposomes. A: Early traditional ‘plain’ liposomes with 
water soluble drug (a) entrapped into the aqueous liposome interior, and 
lipophilic drug (b) incorporated into the liposomal membrane. B: Antibody-
targeted immunoliposome with antibody covalently coupled (c) to the reactive 
phospholipids in the membrane, or hydrophobically anchored (d) into the 
liposomal membrane after preliminary modification with a hydrophobic moiety. C: 
Long-circulating liposome grafted with a protective polymer (e) such as PEG, 
which shields the liposome surface from the interaction with opsonizing proteins 
(f). D: Long-circulating immunoliposome simultaneously bearing both protective 
polymer and antibody, which can be attached to the liposome surface (g) or, 
preferably, to the distal end of the grafted polymeric chain (h). E: New-generation 
liposome, the surface of which can be modified (separately or simultaneously) by 
different ways. Among these modifications are: the attachment of protective 
polymer (i) or protective polymer and targeting ligand, such as antibody (j); the 
attachment/incorporation of a diagnostic label (k); the incorporation of positively 
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charged lipids (l) allowing for the complexation with DNA yielding lipoplex 
structures (m); the incorporation of stimuli-sensitive lipids (n); the attachment of a 
stimuli-sensitive polymer (o); the attachment of a cell-penetrating peptide (p); the 
incorporation of viral components (q). In addition to a drug, liposomes can be 
loaded with magnetic particles (r) for magnetic targeting and/or with colloidal 
gold, silver particles or fluorescent molecules (s) for microscopic analysis. 
Adapted with permission from reference 11. 
 
Figure 3. Depletion of tumor associated macrophages in combination with 
liposomal chemotherapy. Treatment of F9 teratocarcinoma tumors in 
syngeneic Sv129 mice, either with clodronate in plain liposomes (clodrolip) and 
5-FdU-NOAC in pegylated long circulating liposomes alone (black triangles) or in 
combination (open diamonds). Phosphate buffer (PBS) treated controls are 
shown with open squares. The experiment was performed as described in 
reference 36. 
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